Prevalence of primary HIV-1 drug resistance among recently infected adolescents: a multicenter adolescent medicine trials network for HIV/AIDS interventions study

J Infect Dis. 2006 Dec 1;194(11):1505-9. doi: 10.1086/508749. Epub 2006 Oct 20.

Abstract

This study examined the prevalence of primary human immunodeficiency type 1 (HIV-1) drug resistance among recently infected youth in the United States. Of the 55 subjects studied, major mutations conferring HIV drug resistance were present in 10 (18%). Eight (15%) had nonnucleoside reverse-transcriptase inhibitor (NNRTI) mutations, with the majority (6) having the K103N mutation; 2 (4%) had nucleoside reverse-transcriptase inhibitor (NRTI) mutations; and 2 (4%) had protease inhibitor (PI) mutations. Phenotypic drug resistance was present in 12 (22%) subjects: 10 (18%) for NNRTIs, 2 (4%) for NRTIs, and 3 (5.5%) for PIs. The prevalence of primary HIV-1 drug resistance, particularly to NNRTIs, in this group of recently infected youth was high.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Amino Acid Substitution / genetics
  • Anti-HIV Agents / pharmacology*
  • Child
  • Drug Resistance, Viral / genetics*
  • Female
  • HIV Infections / epidemiology
  • HIV Infections / virology*
  • HIV Protease / genetics
  • HIV Reverse Transcriptase / genetics
  • HIV-1 / drug effects*
  • HIV-1 / genetics*
  • Humans
  • Male
  • Mutation

Substances

  • Anti-HIV Agents
  • HIV Reverse Transcriptase
  • HIV Protease